Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) SVP Mark Brosius sold 489 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $533.18, for a total transaction of $260,725.02. Following the transaction, the senior vice president now owns 2,091 shares in the company, valued at $1,114,879.38. The trade was a 18.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Mark Brosius also recently made the following trade(s):
- On Wednesday, March 5th, Mark Brosius sold 492 shares of Intuitive Surgical stock. The shares were sold at an average price of $554.17, for a total transaction of $272,651.64.
- On Monday, March 3rd, Mark Brosius sold 492 shares of Intuitive Surgical stock. The stock was sold at an average price of $573.78, for a total transaction of $282,299.76.
Intuitive Surgical Stock Performance
NASDAQ:ISRG traded down $20.31 during trading hours on Friday, reaching $518.26. The stock had a trading volume of 3,687,590 shares, compared to its average volume of 1,401,377. The stock has a market cap of $184.59 billion, a P/E ratio of 80.85, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The stock has a 50 day simple moving average of $571.70 and a 200 day simple moving average of $530.95. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.
Institutional Investors Weigh In On Intuitive Surgical
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on ISRG. Jefferies Financial Group upped their price target on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Raymond James increased their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Evercore ISI boosted their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Wells Fargo & Company boosted their price objective on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price objective (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.
Read Our Latest Analysis on Intuitive Surgical
Intuitive Surgical Company Profile
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Featured Stories
- Five stocks we like better than Intuitive Surgical
- How to trade penny stocks: A step-by-step guide
- Is Myers Industries Poised for a Breakout?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.